Introduction
============

Multitargeted tyrosine kinase inhibitors (TKIs) have revolutionised the treatment of metastatic clear cell renal cancer ([@b9-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]; [@b4-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]). Sunitinib has superseded cytokine therapy as first line treatment for this disease ([@b8-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]).

Patient results after treatment with cytokine therapy have been reported ([@b13-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]; [@b14-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]; [@b15-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]; [@b7-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]; [@b11-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]), but currently there are no data on treatment and outcome after progression on sunitinib therapy.

Single agent chemotherapy has little effect in metastatic clear cell renal cancer ([@b6-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]; [@b2-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]). However, the role of combination chemotherapy in cytokine refractory disease was already under investigatation before the introduction of TKIs ([@b13-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]; [@b15-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]; [@b11-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]; [@b10-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]). Our group published a phase II study using irinotecan cisplatin and mitomycin (IPM) in cytokine refractory disease ([@b14-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]). Results were comparable to historical controls treated with chemotherapy, with a progression-free survival of 4.8 months and overall survival (OS) of 9.2 months.

We have continued to use IPM in patients with refractory renal cell cancer and in this short report we describe our experience (as part of a prospective observational study) using this regimen after progression on sunitinib therapy.

Methods
=======

Since the publication of the IPM regimen ([@b14-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]) the policy of our unit has been to offer this treatment to patients with sunitinib refractory metastatic renal cancer. Patients with histologically confirmed metastatic clear cell renal cancer, who were progressing on (RECIST criteria) (n = 10) or intolerant to sunitinib (n = 1), were included, after giving informed consent according to standard guidelines. CT scanning of the chest, abdomen, and pelvis was performed every 2 complete cycles of treatment.

The IPM regimen
---------------

Treatment was administered on an outpatient basis as follows: intravenous (iv) irinotecan 70 mg/m^2^, cisplatin 40 mg/m^2^, mitomycin-C 6 mg/m^2^ was administered on day 1, and irinotecan 70 mg/m^2^, cisplatin 40 mg/m^2^ was administered on day 15 of a 28-day cycle. Anti-emetic granisetron 1 mg iv and dexamethasone 8 mg iv were co-administered routinely with each cycle. Blood cell counts and chemistry panels were repeated with every treatment. Treatment was delayed by one week in the event of bone marrow suppression (total leukocyte count \<3 × 10^9^ cells/L, neutrophil count \<1.5 × 10^9^ cells/L, or platelet count \<100 × 10^9^ cells/L). This regimen has been standard second line therapy for metastatic renal tumors at our unit since the publication of our work in 2003 ([@b14-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]).

Statistics
----------

Survival was calculated according to the method of Kaplan and Meier.

Results ([Table 1](#t1-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin){ref-type="table"})
===================================================================================================

The median age of the 11 patients with clear cell renal tumors was 53.5 (range: 42--69). The median OS from time of diagnosis of metastatic renal cancer was 20.5 months (range: 6.1--19.7).

Treatment prior to IPM chemotherapy
-----------------------------------

### Cytokine therapy

The Memorial Sloan Kettering risk factors for these patients at initial diagnosis were: poor risk disease (n = 1), intermediate risk disease (n = 8), and favourable risk disease (n = 2). All but 1 patient had had a nephrectomy and all had received immune therapy as first line therapy followed by sunitinib therapy as second line therapy. None of the patients responded to immune therapy (interferon-alpha n = 9, interferon, 5FU, and il-2 n = 2) and the median time to progression on cytokine therapy was 4 months (range: 2--17 months).

### Sunitinib therapy

All 11 patients went on to receive sunitinib therapy. Two patients had progression of disease, 5 had stable disease, and 4 had a partial response to treatment after 2 cycles of therapy. The median number of cycles administered was 4 and the median time on therapy was 7.2 months (range: 2.1--11.3 weeks). The prognostic factors for these pre-treated patients are shown in [Table 1](#t1-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin){ref-type="table"}.

Response to IPM chemotherapy post sunitinib therapy
---------------------------------------------------

Only 2 patients received all 4 cycles of IPM chemotherapy as planned. All but 2 patients progressed either clinically or radiologically by the end of the second cycle of chemotherapy. One patient had stable disease but did not complete treatment (due to grade 3 toxicity), while the other had a partial response to treatment. This patient is alive and continues in remission 11 months after chemotherapy. The median time to progression from time of starting chemotherapy was 1.4 months (95% CI: 0.9--2.3 months), while the OS was 4.2 months (95% CI:1.6--6.2 months). Ten patients have died of progressive renal cancer ([Figures 1](#f1-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin){ref-type="fig"} and [2](#f2-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin){ref-type="fig"}).

Toxicity associated with IPM chemotherapy
-----------------------------------------

Four of the 11 patients required a dose reduction for grade 3 or grade 4 toxicity, which included diarrhea (n = 2) and neutropenic sepsis (n = 1) and lethargy (n = 2). One of these patients stopped the IPM after 3 cycles because of toxicity.

Discussion
==========

Sunitinib is now widely used as first line therapy in metastatic clear cell renal cancer. There are no published data on the management of patients with progression of disease on sunitinib therapy. Importantly, it is not clear whether patients should stop sunitinib therapy at progression ([@b9-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin], [@b8-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]). The use of sequential TKIs, such as a switch from sunitinib to sorafenib or axitinib on progression is common, but not yet of proven benefit ([@b10-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]). These sequential regimens are undergoing intense prospective evaluation and the results are eagerly awaited.

It is widely accepted that renal cancer is largely resistent to chemotherapy in the majority of patients. The data presented here describes 11 patients who switched to IPM chemotherapy at progression (n = 10) or intolerance (n = 1) after sunitinib. The median time to progression (TTP) and median OS were 1.4 and 4.2 months, respectively. These results appear shorter when compared with IPM after cytokine therapy (TTP 4.8 months and OS 9.2 months) ([@b14-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]). Although the numbers are small, the data suggest that IPM chemotherapy in this setting does not appear to be of benefit. One patient did respond to therapy, but the significance of this is not clear ([@b3-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]). Moreover this regimen was not particularly well tolerated in this setting with more than a third of the patients developing grade 3 or 4 toxicity. This finding, in conjunction with the poor response data, prompted us to halt further use of this regimen in this setting.

A number of prognostic factors have been identified for patients who have progressed on cytokine therapy ([@b7-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]). Eight of the 11 patients presented here were in this poor prognosis group. The median survival for these patients is predicted to be only 5.4 months, which may help explain, in part, why the results are poor. Indeed future investigation in this area should perhaps focus on patients with better prognostic factors.

There are 3 other possible explanations for these poor results. Firstly IPM was used as third line rather than second line therapy (after cytokine failure and sunitinib failure). Secondly, patients who progress on sunitinib may have more advanced and aggressive disease at the time of progression, compared with those who fail on cytokine therapy. This issue is unresolved in previously published studies ([@b9-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]), although such results might be expected to indicate higher response rates with chemotherapy than those seen in this work. Finally, it is possible that stopping sunitinib is associated with acceleration of disease, as seen with imatinib in gastro-intestinal stromal tumors (GIST) ([@b1-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]).

The results of the IPM regimen, in the cytokine refractory setting, are comparable to other combination regimes used in this setting (gemicitabine and 5FU: TTP 6.6 months, OS 11 months ([@b12-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]); gemicitabine and oxaliplatin TTP 2.5 months, mean OS 9.5 months ([@b11-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]). The addition of cisplatin to gemicitabine and 5FU did not enhance these results any further ([@b5-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin]). Therefore one would not necessarily expect the results with these other chemotherapy regimes to be dramatically different, although the in vitro data on this topic is limited. Nevertheless the response and survival data presented here is poor and, in our opinion, does not warrant further investigation in this setting.

In view of the poor survival rates of these patients, this may not be the ideal setting to investigate new treatment in isolation in renal cancer. Other studies may wish to recruit patients with better prognostic factors or add treatments to sunitinib rather than stop it. It does not appear that IPM chemotherapy benefits patients with metastatic clear cell renal cancer who previously received sunitinib therapy.
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###### 

Patient characteristics and outcome

  Risk at time of sunitinib therapy ([@b7-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin])   Initial response to sunitinib therapy   TTP during sunitinib therapy   Risk at time of IPM ([@b7-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin])   Response to IPM after 2 cycles   Grade 3 or 4 toxicity on IPM   TTP on IPM (months)                                                                             Overall survival from time of starting IPM (months)                                            Overall survival from time of diagnosis of metastatic renal cancer
  ---------------------------------------------------------------------------------------------------- --------------------------------------- ------------------------------ -------------------------------------------------------------------------------------- -------------------------------- ------------------------------ ----------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------
  int                                                                                                  PR                                      14.3                           int                                                                                    PD                               --                             1,4                                                                                             4.2                                                                                            31
  *Poor*                                                                                               PD                                      2.8                            poor                                                                                   PD                               --                             0.5                                                                                             0.5                                                                                            6.1
  *Int*                                                                                                PD                                      4.8                            poor                                                                                   PD                               Dia                            0.9                                                                                             2.1                                                                                            9.2
  *Int*                                                                                                SD                                      8.3                            poor                                                                                   PD                               --                             1.8                                                                                             3.0                                                                                            27.4
  *Good*                                                                                               PR                                      12.2                           poor                                                                                   PD                               Dia, lethergy                  1.4                                                                                             1.6                                                                                            33.0
  *Poor*                                                                                               SD                                      7.2                            int                                                                                    PD                               Lethargy                       2.8                                                                                             6.2                                                                                            16.9
  *int*                                                                                                PR                                      6.2                            poor                                                                                   PR                               --                             11.0[PF](#tfn2-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin){ref-type="table-fn"}   11.0[A](#tfn1-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin){ref-type="table-fn"}   34.3[A](#tfn1-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin){ref-type="table-fn"}
  *Poor*                                                                                               SD                                      2.1                            poor                                                                                   SD                               Neut. Sepsis. Lethargy         2.3[T](#tfn3-ott_3590_the_efficacy_and_safety_of_irinotecan_cisplatin){ref-type="table-fn"}     7.8                                                                                            18.1
  *int*                                                                                                SD                                      10.5                           poor                                                                                   PD                               --                             0.9                                                                                             5                                                                                              20.5
  *poor*                                                                                               SD                                      2.7                            poor                                                                                   PD                               --                             1.8                                                                                             5.3                                                                                            24.4
  *Int*                                                                                                PR                                      11.3                           int                                                                                    PD                               --                             1.4                                                                                             2.1                                                                                            15.6

**Notes:** Alive

Progression free

Stopped due to toxicity.

**Abbreviations**: TTP, time to progression; Int, intermediate; Neut, neutropenic; Dia, diarrhea.
